From discovery to development

An innovative NGS portfolio to accelerate drug development

NGS for Drug Development

Illumina provides an innovative portfolio of next-generation sequencing (NGS) systems, products, and services for the drug development pipeline. With solutions to inform the drug development process, you can confidently choose us as a partner from discovery through companion diagnostics development.

NGS approaches can generate multiple levels of genomic data essential for drug development, from genomic modifications to transcriptome profiling and quantification, epigenetic modifications, and more.

We are uniquely positioned to deliver products and services to support pharmaceutical development with the largest install base of NGS instrumentation.

Approximately 90 percent of all sequencing data produced today has been generated using Illumina technologies*. Reference and service labs are installing our instruments in increasing numbers to perform a wide variety of applications.

The Illumina portfolio informs multiple stages of the drug discovery and pharmaceutical development process, from target identification to post approval.

Click on the below to view methods and products supporting the various drug discovery and development stages.

Whole-Genome Sequencing (WGS)

Take a comprehensive view of the genomic variation linked to a pathway.

Whole-Exome Sequencing

Explore genomic variation in the protein-coding regions of the genome as a cost-effective alternative to WGS.

RNA Sequencing

Characterize expression by sequencing individual targets or the entire transcriptome.

Cancer Sequencing Methods

Perform whole-genome studies, targeted gene profiling, tumor-normal comparisons, ctDNA sequencing, and more.

TruSight Oncology 500 Product Family

Enabling comprehensive genomic profiling from both blood and tissue samples.

Immuno-Oncology Research

NGS methods enable efficient, broad, and deep assessment of tumors and their microenvironment.

Drug Response RNA Biomarker Discovery

Learn how to use RNA-Seq to identify novel RNA-based drug response biomarkers.

Epigenetics

Find NGS and microarray tools to study epigenetic modifications and their impact on gene regulation.

Sequencing Platforms

Find the sequencing system that best fits your scale of study.

Bioinformatics Tools

User-friendly tools to guide you from experimental design to data interpretation and reporting.

Genomic Services

Find an Illumina service provider to support your genomics needs.

Cancer Sequencing Methods

Perform whole-genome studies, targeted gene profiling, tumor-normal comparisons, ctDNA sequencing, and more.

TruSight Oncology 500 Product Family

Enabling comprehensive genomic profiling from both blood and tissue samples.

Cancer RNA Sequencing

Confirm expression in transcripts of interest with targeted panels and access hard-to-analyze FFPE samples. Or leverage RNA-Seq to discover and profile RNA-based drug response biomarkers.

Immuno-Oncology Research

NGS methods enable efficient, broad, and deep assessment of tumors and their microenvironment

Sequencing Platforms

Find the sequencing system that best fits your scale of study.

Informatics

User-friendly tools guide you from experimental design to data interpretation and reporting.

Genomic Services

Find an Illumina service provider to support your genomics needs.

Cancer Sequencing Methods

Perform whole-genome studies, targeted gene profiling, tumor-normal comparisons, ctDNA sequencing, and more.

TruSight Oncology 500 Product Family

Enabling comprehensive genomic profiling from both blood and tissue samples.

Cancer RNA Sequencing

Confirm expression in transcripts of interest with targeted panels and access hard-to-analyze FFPE samples. Or leverage RNA-Seq to discover and profile drug response RNA biomarkers.

Immuno-Oncology Research

NGS methods enable efficient, broad, and deep assessment of tumors and their microenvironment.

Sequencing Platforms

Find the sequencer that best fits your scale of study.

Informatics

User-friendly tools guide you from experimental design to data interpretation and reporting.

Genomic Services

Find an Illumina service provider to support your genomics needs.

Explore our unique, multi-analyte approach to co-development.

Cancer Sequencing Methods

Perform whole-genome studies, targeted gene profiling, tumor-normal comparisons, ctDNA sequencing, and more.

TruSight Oncology 500 Product Family

Enabling comprehensive genomic profiling from both blood and tissue samples.

Cancer RNA Sequencing

Confirm expression in transcripts of interest with targeted panels and access hard-to-analyze FFPE samples.

Immuno-Oncology Research

NGS methods enable efficient, broad, and deep assessment of tumors and their microenvironment.

Sequencing Platforms

Find the sequencer that best fits your scale of study.

Companion Diagnostics Development

Explore our unique, multi-analyte approach to co-development.

High-Throughput Genotyping Research Tools

Gain meaningful insights from complex populations.

Informatics

User-friendly tools guide you from experimental design to data interpretation and reporting.

Genomic Services

Find an Illumina service provider to support your genomics needs.

Companion Diagnostic Development

Explore our unique, multi-analyte approach to co-development.

MiSeqDx Instrument

Discover the first FDA-cleared next-generation sequencing system.

NextSeq 550Dx Instrument

Explore the next level in diagnostic power for the clinical lab.

High-Throughput Genotyping Research Tools

Gain meaningful insights from complex populations.

Genomic Services

Find an Illumina service provider to support your genomics needs.

 

Exclusive Offer for TruSight Oncology 500

Purchase the TruSight Oncology 500 assay for the first time and receive an exclusive limited time offer.

Learn More
Exclusive Offer for TruSight Oncology 500

Scientists Discuss Drug Discovery Projects

GLOBAL Clinical Study Demonstrates Value of Panomics-Based Drug Discovery Approach
Value of a Panomics-Based Drug Discovery Approach

Integrating imaging, multiomic technologies, and big data uncovers novel diagnostic and therapeutic targets for common chronic diseases.

Read Interview
Tumor
Beyond Single-Drug Approaches to Precision Oncology

Researchers utilize transcriptomics to uncover multiple drug-susceptible tumorigenic pathways.

Read Interview
The Time is Now for Microbiome Studies
Advancing Drug Discovery with Microbiome Studies

Whole-genome shotgun sequencing and transcriptomics provide pharmaceutical scientists with data to refine drug discovery and development.

Read Interview

Dr. Jeffrey Conroy, Chief Scientific Officer of OmniSeq, Inc., discusses the value of combining genomic and immune profiling. He also showcases the impact of a scalable comprehensive assay and infrastructure in the context of drug development.

View Webinar
Fluorescent DNA helix
Cancer
Cancer Research

NGS-based methods allow cancer researchers to detect rare somatic variants, tumor subclones, and circulating DNA fragments. Learn more about cancer genomics.

Microbiology
Microbial Sequencing

From metagenomics and microbiome studies to infectious disease surveillance, NGS can help researchers gain genetic insight into bacteria and viruses. Learn more about microbial genomics.

Complex Diseases
Complex Disease Research

Sequencing is introducing new avenues for understanding autoimmune diseases, atherosclerosis, neurological diseases, and psychiatric disorders on a molecular level. Learn more about complex disease genomics.

Rare Diseases
Rare disease researchers pipetting

NGS can help scientists uncover genetic variants associated with rare and undiagnosed disorders. Learn more about rare disease genomics.

Interested in receiving newsletters, case studies, and information on genomics in drug development? Enter your email address.
NGS Used for Biological QC in BioPharma Production
NGS Used for Biological QC in BioPharma Production

Read how Merck Serono uses NGS for cell line stability testing and biosafety monitoring.

Access PDF
RNA-Seq for Drug Response Biomarker Discovery and Profiling
RNA-Seq for Drug Response Biomarker Discovery and Profiling

Access resources to explore NGS-based biomarker discovery and profiling.

View Resources
Polygenic Risk Scores
Polygenic Risk Scores

Polygenic risk scores represent the total number of genetic variants that an individual has to assess their heritable risk of developing a particular disease.

Learn More
Scaling NGS to Deliver Discoveries
Scaling NGS to Deliver Discoveries

Regeneron discusses their latest work and overall mission to explore new variations in genomes that can help explain disease.

View Video

* Data calculations on file. Illumina, Inc. 2017.